NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration state ...

诉讼案件概述 - Levi & Korsinsky律师事务所通知Zenas BioPharma投资者有关证券集体诉讼事宜 诉讼旨在代表因涉嫌证券欺诈而遭受损失的投资者追偿损失 [1][2] - 诉讼适用于在2024年9月Zenas BioPharma首次公开募股期间根据注册声明及相关招股说明书购买或获得公司证券的投资者 [2] 诉讼指控内容 - 指控被告方存在虚假陈述及隐瞒行为 具体包括Zenas BioPharma严重夸大其利用现有现金及IPO预期净收益维持运营的时间长度 [3] - 指控被告方的公开声明在所有相关时间均存在重大虚假和误导性 且准备工作存在疏忽 [3] 诉讼参与信息 - 受影响投资者需在2025年6月16日前向法院申请成为首席原告 但参与赔偿无需担任首席原告角色 [4] - 集体诉讼成员可能无需支付任何自付费用即可获得赔偿 参与无成本或义务 [4] 律所背景 - Levi & Korsinsky过去20年为受损股东追回数亿美元 在高风险案件中保持胜诉记录 [5] - 该律所在复杂证券诉讼领域拥有丰富经验 团队规模超70人 连续七年入选ISS证券集体诉讼服务Top 50报告 [5] 联系方式 - 诉讼联系渠道包括电子邮件、电话及在线表单 具体联系人为Joseph E Levi和Ed Korsinsky [2][6] - 律所地址位于纽约白厅街33号17层 提供传真及官网等详细信息 [6]

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=147756&from=3 CLASS PERIOD: This ...

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=147726&from=4CLASS PERIOD: This lawsuit ...

诉讼案件概述 - 证券律师事务所Cohen Milstein正在积极寻找投资者作为针对Zenas BioPharma集体诉讼的首席原告 诉讼指控公司在2024年9月IPO时作出 materially misleading statements [1] - 提交首席原告动议的截止日期为2025年6月16日 [1] 诉讼指控内容 - 诉讼在美国马萨诸塞州地方法院提起 指控Zenas BioPharma及多家承销商在IPO注册材料中夸大公司财务 runway [4] - 公司IPO时预测可用资本可持续24个月 但在2024年Q3财报中承认仅能维持12个月运营 [4] - 该披露后 ZBIO股价下跌49% 截至2025年4月15日收盘价为8 72美元 [4] 首席原告作用 - 首席原告代表全体集体成员指导诉讼 包括案件策略和和解谈判 [5] - 投资者无需担任首席原告也可获得赔偿 但损失较大的投资者常选择此角色以监督案件积极进展 [5] 律所背景 - Cohen Milstein是美国最受认可的证券诉讼律所之一 其证券诉讼业务被The Legal 500 Law360等权威法律媒体评为行业领导者 [6] - 该律所近期作为联席首席顾问参与Wells Fargo证券诉讼案 为受欺诈投资者争取到10亿美元和解金 [6]

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement a ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration state ...

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=147319&from=4 CLASS PERIOD: This lawsuit ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement a ...

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development an ...